Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

LAG3 overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

LAG3 overexpression	Non Small Cell Lung Cancer	LAG3 overexpression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO 2023 - 2 weeks - (New C3)
LAG3 overexpression	Diffuse Large B Cell Lymphoma	LAG3 overexpression	Diffuse Large B Cell Lymphoma	MGD013 Sensitive: C3 – Early Trials MGD013 Sensitive : C3	MGD013 Sensitive: C3 – Early Trials MGD013 Sensitive : C3
LAG3 overexpression	Soft Tissue Sarcoma	LAG3 overexpression	Soft Tissue Sarcoma	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3
LAG3 overexpression	Melanoma	LAG3 overexpression	Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3